Canada markets closed

Citius Pharmaceuticals, Inc. (CTXR)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
0.6600-0.0242 (-3.54%)
At close: 04:00PM EDT
0.6700 +0.01 (+1.52%)
After hours: 07:43PM EDT
Full screen
Trade prices are not sourced from all markets
Previous Close0.6842
Open0.6721
Bid0.6257 x 600
Ask0.6942 x 600
Day's Range0.6500 - 0.7000
52 Week Range0.6000 - 1.4000
Volume1,782,597
Avg. Volume1,405,163
Market Cap119.244M
Beta (5Y Monthly)1.54
PE Ratio (TTM)N/A
EPS (TTM)-0.2300
Earnings DateAug 12, 2024 - Aug 16, 2024
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est4.00
  • PR Newswire

    Citius Pharmaceuticals Achieves Primary and Secondary Endpoints in Phase 3 Trial of Mino-Lok Antibiotic Lock Solution

    Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a late-stage biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products, today announced positive topline results of its pivotal Phase 3 clinical trial of Mino-Lok®, a novel antibiotic lock solution designed to salvage catheters in patients with central line-associated infections (CLABSI) or catheter-related bloodstream infections (CRBSI). The study met its primary

  • PR Newswire

    Citius Pharmaceuticals, Inc. Reports Fiscal Second Quarter 2024 Financial Results and Provides Business Update

    Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a late-stage biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products today reported business and financial results for the fiscal second quarter 2024 ended March 31, 2024.

  • PR Newswire

    Citius Pharmaceuticals to Participate in Upcoming EF Hutton and H.C. Wainwright Investor Conferences

    Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a late-stage biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products, today announced its participation in two upcoming investor conferences. Citius Chairman and CEO Leonard Mazur will host one-on-one investor meetings at the EF Hutton Annual Global Conference on May 15, 2024, and present and host one-on-one investor meetings at the H.C. Wainwright BioConnect Inv